Who are Pregabalin add-on therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gabapentin Capsules, pregabalin capsules, Standard dose gabapentin, Placebo matched with pregabalin, Perioperative Pregabalin, Neurontin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pregabalin-add-on-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Pregabalin add-on therapy — Competitive Intelligence Brief

Pregabalin add-on therapy (Pregabalin add-on therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gabapentinoid. Area: Neurology.

phase 3 Gabapentinoid Alpha-2-delta-1 subunit of voltage-gated calcium channels Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Pregabalin add-on therapy (Pregabalin add-on therapy) — Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pregabalin add-on therapy TARGET	Pregabalin add-on therapy	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	phase 3	Gabapentinoid	Alpha-2-delta-1 subunit of voltage-gated calcium channels
Gabapentin Capsules	Gabapentin Capsules	EpiCept Corporation	marketed	Anticonvulsant; Gabapentinoid	Alpha-2-delta-1 subunit of voltage-gated calcium channels
pregabalin capsules	pregabalin capsules	AstraZeneca	marketed	Gabapentinoid; anticonvulsant; anxiolytic	Alpha-2-delta-1 subunit of voltage-gated calcium channels
Standard dose gabapentin	Standard dose gabapentin	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant; gabapentinoid	Alpha-2-delta-1 subunit of voltage-gated calcium channels
Placebo matched with pregabalin	Placebo matched with pregabalin	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	phase 3	Gabapentinoid	Alpha-2-delta-1 subunit of voltage-gated calcium channels
Perioperative Pregabalin	Perioperative Pregabalin	McMaster University	phase 3	Gabapentinoid; anticonvulsant; anxiolytic analgesic	Alpha-2-delta-1 subunit of voltage-gated calcium channels
Neurontin	gabapentin	Generic (originally Parke-Davis/Pfizer)	marketed	Gabapentinoid (anticonvulsant/neuropathic pain agent)	Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor	1993-12-30

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gabapentinoid class)

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pregabalin add-on therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/pregabalin-add-on-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab